8-K
filed May 27, 2026, 4:57 PM ET
ticker DRMA
CIK 0001853816
other material
confidence high
sentiment neutral
materiality 0.50
Dermata shareholders approve 2021 equity plan increase to 402,214 shares
Dermata Therapeutics, Inc.
- Elected David Hale, Steven Mento Ph.D., and Brittany Bradrick as Class II directors.
- Ratified CBIZ CPAs P.C. as independent auditor for FY2026.
- Approved issuance of shares underlying warrants (exceeding 20% of outstanding common stock).
- Approved repricing of warrants exercisable for up to 120,734 common shares.
- Approved adjournment proposal to allow sufficient votes on other proposals.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dermata Therapeutics, Inc. shareholders approved Approval of the repricing of warrants exercisable for up to 120,734 shares of Common Stock (Warrant Repricing Proposal).
- Outcome
- passed
Exact text from the filing
The Warrant Repricing Proposal was approved based upon the following votes: For Against Abstain Broker Non-Votes 439,573 21,203 845,039 1,068,656
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dermata Therapeutics, Inc. shareholders approved Approval of an amendment to the 2021 Plan to increase the maximum aggregate number of shares reserved for issuance to 402,214 shares (Plan Amendment Proposal).
- Proposal
- equity plan
- Outcome
- passed
Exact text from the filing
The Plan Amendment Proposal was approved based upon the following votes: For Against Abstain Broker Non-Votes 1,243,540 47,441 14,834 1,068,656
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dermata Therapeutics, Inc. shareholders approved Election of three Class II directors.
- Proposal
- director election
- Outcome
- passed
Exact text from the filing
The stockholders elected David Hale, Steven Mento, Ph.D. and Brittany Bradrick as Class II directors to serve until the 2029 annual meeting and until their successors have been duly elected and qualified. The votes were cast for this matter as follows: Nominee For Withheld Broker Non-Votes David Hale 1,258,269 47,546 1,068,656 Steven Mento Ph.D. 1,258,871 46,944 1,068,656 Brittany Bradrick 1,262,134 43,681 1,068,656
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dermata Therapeutics, Inc. shareholders approved Approval of the adjournment of the Annual Meeting to solicit additional votes (Adjournment Proposal).
- Outcome
- passed
Exact text from the filing
The Adjournment Proposal was approved based upon the following votes: For Against Abstain 1,269,857 21,137 14,821
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dermata Therapeutics, Inc. shareholders approved Approval of the issuance of shares of Common Stock underlying certain warrants in an amount equal to or in excess of 20% of the Common Stock outstanding immediately prior to the issuance of such warrants (Issuance Proposal).
- Outcome
- passed
Exact text from the filing
The Issuance Proposal was approved based upon the following votes: For Against Abstain Broker Non-Votes 315,477 22,696 967,642 1,068,656
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Dermata Therapeutics, Inc. shareholders approved Ratification of the appointment of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal
- auditor ratification
- Outcome
- passed
Exact text from the filing
The Auditor Proposal was approved based upon the following votes: For Against Abstain 2,329,537 43,122 1,812
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.